What Is Considered a Good Stock Dividend? 3 Healthcare Stocks That Fit the Bill.

The article highlights three healthcare dividend stocks—AbbVie, UnitedHealth Group, and CVS Health—as attractive options for institutional investors seeking consistent returns. AbbVie reported robust Q3 revenue of $15.8 billion, up 9.1%, driven by Skyrizi and Rinvoq, and increased its dividend by 5.5% to yield 3.1%. UnitedHealth Group, despite a 34% YTD stock decline due to earlier claim misjudgments, showed Q3 revenue up 12% to $113.2 billion and raised its full-year EPS guidance, offering a 2.6% dividend yield. CVS Health demonstrated strong Q3 performance with revenue up 7.8% to $102.8 billion and adjusted operating income up 35%, with its stock up 74% YTD and yielding 3.4%.

Analysis

The healthcare sector presents compelling opportunities for dividend-seeking institutional investors, with three distinct profiles highlighted. AbbVie (ABBV) demonstrates robust financial health, reporting Q3 revenue of $15.8 billion, a 9.1% year-over-year increase, primarily driven by Skyrizi and Rinvoq, which saw revenue growth of 46.8% and 35.3% respectively, effectively offsetting the anticipated 55.4% decline in Humira sales. The company's commitment to shareholder returns is evident in its 5.5% dividend increase, raising it to $1.73 per share, contributing to its 3.1% yield and 20% YTD stock appreciation.

UnitedHealth Group (UNH), despite a challenging year with its stock down 34% due to a $6.5 billion misjudgment in medical claims, shows signs of a potential turnaround. Its Q3 revenue grew 12% year-over-year to $113.2 billion, prompting an upward revision of its full-year adjusted EPS outlook by $0.25 to $16.25. Strategic adjustments to Medicare Advantage benefits and pricing for 2026 and 2027 are underway to improve margins, with analysts anticipating a stronger stock performance in 2026, supported by its 2.6% dividend yield.

CVS Health (CVS) exhibits significant momentum, with its stock up 74% YTD, underpinned by strong Q3 financial results. The company reported revenue of $102.8 billion, up 7.8% year-over-year, and a substantial 35% increase in adjusted operating income to $3.45 billion, alongside improved EPS of $1.60. Its diversified model, encompassing retail, insurance, and primary care post-Aetna acquisition, provides broad revenue streams, and it offers an attractive 3.4% dividend yield, reinforcing its appeal as a growth and income play.

Key Decisions for Investors

• Investors should consider AbbVie for its robust pipeline growth offsetting patent expirations and its commitment to increasing shareholder dividends, offering a blend of growth and income.
• UnitedHealth Group presents a potential turnaround opportunity, warranting close monitoring of its 2026-2027 margin improvement initiatives and their impact on stock performance.
• CVS Health appears attractive for its strong Q3 operational performance, diversified healthcare ecosystem, and significant YTD stock appreciation, providing both momentum and a solid dividend yield.